The Future of Precision Oncology
We provide innovative protein technology for pancreatic cancer
Reccan Diagnostics is a company based on research performed at Lund University. We have developed a biotechnology platform for in vitro diagnostics, providing both earlier and more specific diagnosis, as well as improved prognostic stratification of solid cancers. The technology platform is based on a patented combination of unique protein biomarkers detectable in blood and cancer tissue samples. The primary focus area is pancreatic cancer, currently the third leading cause of cancer-related death. Pancreatic cancer is projected to become the second cause of cancer death within a few years if no action is taken.
Pancreatic cancer is a disease where early detection substantially improves the prognosis for the patient. A diagnostic test for pancreatic cancer should be simple, accurate and non-invasive.